|
| 36632791 | EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection. | Neuro Oncol | 2023 |
| 37727848 | Loss of H3K27me3 in meningiomas: an independent marker for CNS WHO grade 2? | Neurooncol Adv | 2023 |
| 35838837 | The prognostic role of the immunohistochemical expression of S100 in meningiomas. | J Cancer Res Clin Oncol | 2023 |
| 35419607 | Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. | Neuro Oncol | 2023 |
| 37280276 | The German Network for Personalized Medicine to enhance patient care and translational research. | Nat Med | 2023 |
| 37171636 | Correction: Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas. | Acta Neuropathol | 2023 |
| 37335962 | Intraoperative MRI-Guided Resection Is Not Superior to 5-Aminolevulinic Acid Guidance in Newly Diagnosed Glioblastoma: A Prospective Controlled Multicenter Clinical Trial. | J Clin Oncol | 2023 |
| 37228396 | Uncovering transcriptomic landscape alterations of CAN-2409 in <i>in vitro</i> and <i>in vivo</i> glioma models. | Front Med (Lausanne) | 2023 |
| 36915613 | Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system. | Neurooncol Adv | 2023 |
| 36843451 | Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults. | Neuro Oncol | 2023 |
| 36609807 | Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial. | J Neurooncol | 2023 |
| 36765625 | Patient Reported and Clinical Outcomes after High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma. | Cancers (Basel) | 2023 |
| 36672508 | Correction: Gonçalves et al. Macrophage and Lymphocyte Infiltration Is Associated with Volumetric Tumor Size but Not with Volumetric Growth in the Tübingen Schwannoma Cohort. <i>Cancers</i> 2021, <i>13</i>, 466. | Cancers (Basel) | 2023 |
| 34353870 | Impact of <sup>18</sup>F-FET PET/MRI on Clinical Management of Brain Tumor Patients. | J Nucl Med | 2022 |
| 35672677 | Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib. | BMC Cancer | 2022 |
| 35639965 | Gender disparity regarding work-life balance satisfaction among German neuro-oncologists: a YoungNOA survey. | Neuro Oncol | 2022 |
| 35599302 | AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas. | Neurol Res Pract | 2022 |
| 35599271 | Correction to: The immunohistochemical expression of SSTR2A is an independent prognostic factor in meningioma. | Neurosurg Rev | 2022 |
| 35908833 | EANO - EURACAN - SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors. | Neuro Oncol | 2022 |
| 36038669 | DEGRO practical guideline for central nervous system radiation necrosis part 1: classification and a multistep approach for diagnosis. | Strahlenther Onkol | 2022 |
| 36038670 | DEGRO practical guideline for central nervous system radiation necrosis part 2: treatment. | Strahlenther Onkol | 2022 |
| 36358353 | Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma. | Brain Sci | 2022 |
| 36032633 | Perturbing DDR signaling enhances cytotoxic effects of local oncolytic virotherapy and modulates the immune environment in glioma. | Mol Ther Oncolytics | 2022 |
| 33899156 | Differences in the expression of SSTR1-5 in meningiomas and its therapeutic potential. | Neurosurg Rev | 2022 |
| 35045869 | Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial. | Trials | 2022 |
| 35017150 | Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models. | J Immunother Cancer | 2022 |
| 34890014 | GLINT: GlucoCEST in neoplastic tumors at 3Â T-clinical results of GlucoCEST in gliomas. | MAGMA | 2022 |
| 34941573 | Tissue metabolites in diffuse glioma and their modulations by IDH1 mutation, histology, and treatment. | JCI Insight | 2022 |
| 35018490 | Frequent FGFR1 hotspot alterations in driver-unknown low-grade glioma and mixed neuronal-glial tumors. | J Cancer Res Clin Oncol | 2022 |
| 34601710 | The immunohistochemical expression of SSTR2A is an independent prognostic factor in meningioma. | Neurosurg Rev | 2022 |
| 33104905 | The role of Simpson grading in meningiomas after integration of the updated WHO classification and adjuvant radiotherapy. | Neurosurg Rev | 2021 |
| 33622704 | Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. | Clin Cancer Res | 2021 |
| 33762734 | A vaccine targeting mutant IDH1 in newly diagnosed glioma. | Nature | 2021 |
| 33641674 | COX2 expression is associated with preoperative tumor volume but not with volumetric tumor growth in vestibular schwannoma. | Neurol Res Pract | 2021 |
| 33562558 | Dynamic Susceptibility Perfusion Imaging for Differentiating Progressive Disease from Pseudoprogression in Diffuse Glioma Molecular Subtypes. | J Clin Med | 2021 |
| 33923363 | Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups. | Vaccines (Basel) | 2021 |
| 33530441 | Macrophage and Lymphocyte Infiltration Is Associated with Volumetric Tumor Size but Not with Volumetric Growth in the Tübingen Schwannoma Cohort. | Cancers (Basel) | 2021 |
| 34966669 | A Continuous Correlation Between Residual Tumor Volume and Survival Recommends Maximal Safe Resection in Glioblastoma Patients: A Nomogram for Clinical Decision Making and Reference for Non-Randomized Trials. | Front Oncol | 2021 |
| 34441747 | ADC-Based Stratification of Molecular Glioma Subtypes Using High b-Value Diffusion-Weighted Imaging. | J Clin Med | 2021 |
| 34821945 | [Neurological symptoms associated with cancer treatment]. | Nervenarzt | 2021 |
| 34433969 | A clinically applicable integrative molecular classification of meningiomas. | Nature | 2021 |
| 34800210 | Increased proliferation is associated with CNS invasion in meningiomas. | J Neurooncol | 2021 |
| 34654395 | Cerebrospinal fluid cytokine levels are associated with macrophage infiltration into tumor tissues of glioma patients. | BMC Cancer | 2021 |
| 34129129 | Correction to: Association of dynamic susceptibility magnetic resonance imaging at initial tumor diagnosis with the prognosis of different molecular glioma subtypes. | Neurol Sci | 2021 |
| 33938076 | Neuro-oncological patients' and caregivers' psychosocial burden during the COVID-19 pandemic-A prospective study with qualitative content analysis. | Psychooncology | 2021 |
| 34181733 | EANO guideline on the diagnosis and management of meningiomas. | Neuro Oncol | 2021 |
| 34073442 | Glioma-Specific Diffusion Signature in Diffusion Kurtosis Imaging. | J Clin Med | 2021 |
| 34063518 | Targeting CSF1R Alone or in Combination with PD1 in Experimental Glioma. | Cancers (Basel) | 2021 |
| 34172069 | Retrospective analysis of recurrence patterns and clinical outcome of grade II meningiomas following postoperative radiotherapy. | Radiat Oncol | 2021 |
| 33258061 | [Diagnosis and therapy of tumors with NTRK gene fusion]. | Pathologe | 2021 |